PF-04745637

PF-04745637 is an experimental drug currently under development for the treatment of chronic cough and pruritus. It is a selective antagonist of the transient receptor potential cation channel subfamily V member 1 (TRPV1), a protein that plays a key role in the sensation of pain and heat.

History

PF-04745637 was first synthesized by Pfizer, a multinational pharmaceutical company, as part of their ongoing research into novel treatments for chronic cough and pruritus. The drug is currently in the early stages of clinical trials.

Mechanism of Action

PF-04745637 works by blocking the TRPV1 receptor, a protein found in nerve cells that is responsible for the sensation of pain and heat. By inhibiting this receptor, PF-04745637 is thought to reduce the sensitivity of the cough reflex and alleviate symptoms of pruritus.

Clinical Trials

As of 2021, PF-04745637 is in Phase 2 clinical trials. These trials aim to evaluate the safety and efficacy of the drug in patients with chronic cough and pruritus. The results of these trials will determine whether PF-04745637 progresses to Phase 3 trials, which would involve a larger number of patients and further evaluate the drug's safety and efficacy.

Potential Applications

If successful in clinical trials, PF-04745637 could provide a new treatment option for patients with chronic cough and pruritus, conditions that currently have limited treatment options. The drug could also potentially be used in the treatment of other conditions associated with the TRPV1 receptor, such as neuropathic pain and inflammatory bowel disease.

See Also

• Pfizer
• Chronic cough
• Pruritus
• Transient receptor potential cation channel subfamily V member 1
• Clinical trial